Severe acute respiratory syndrome (SARS) -: paradigm of an emerging viral infection

被引:85
作者
Berger, A
Drosten, C
Doerr, HW
Stürmer, M
Preiser, W
机构
[1] Goethe Univ Frankfurt, Inst Med Virol, D-60596 Frankfurt, Germany
[2] Bernhard Nocht Inst Trop Med, Hamburg, Germany
关键词
severe acute respiratory syndrome (SARS); coronavirus; SARS-associated coronavirus (SARS-CoV); laboratory diagnosis; transmission; emerging infection; epidemiology; antiviral treatment; World Health Organization (WHO);
D O I
10.1016/j.jcv.2003.09.011
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
An acute and often severe respiratory illness emerged in southern China in late 2002 and rapidly spread to different areas of the Far East as well as several countries around the globe. When the outbreak of this apparently novel infectious disease termed severe acute respiratory syndrome (SARS) came to an end in July 2003, it had caused over 8000 probable cases worldwide and more than 700 deaths. Starting in March 2003, the World Health Organization (WHO) organised an unprecedented international effort by leading laboratories working together to find the causative agent. Little more than one week later, three research groups from this WHO-coordinated network simultaneously found evidence of a hitherto unknown coronavirus in SARS patients, using different approaches. After Koch's postulates had been fulfilled, WHO officially declared on 16 April 2003 that this virus never before seen in humans is the cause of SARS. Ever since, progress around SARS-associated coronavirus (SARS-CoV) has been swift. Within weeks of the first isolate being obtained, its complete genome was sequenced. Diagnostic tests based on the detection of SARS-CoV RNA were developed and made available freely and widely; nevertheless the SARS case definition still remains based on clinical and epidemiological criteria. The agent's environmental stability, methods suitable for inactivation and disinfection, and potential antiviral compounds have been studied, and development of vaccines and immunotherapeutics is ongoing. Despite its grave consequences in humanitarian, political and economic terms, SARS may serve as an example of how much can be achieved through a well-coordinated international approach, combining the latest technological advances of molecular virology with more "traditional" techniques carried out to an excellent standard. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:13 / 22
页数:10
相关论文
共 67 条
  • [1] Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs
    Anand, K
    Ziebuhr, J
    Wadhwani, P
    Mesters, JR
    Hilgenfeld, R
    [J]. SCIENCE, 2003, 300 (5626) : 1763 - 1767
  • [2] [Anonymous], 2003, WHOSDEWSH030475
  • [3] Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
    Booth, CM
    Matukas, LM
    Tomlinson, GA
    Rachlis, AR
    Rose, DB
    Dwosh, HA
    Walmsley, SL
    Mazzulli, T
    Avendano, M
    Derkach, P
    Ephtimios, IE
    Kitai, I
    Mederski, BD
    Shadowitz, SB
    Gold, WL
    Hawryluck, LA
    Rea, E
    Chenkin, JS
    Cescon, DW
    Poutanen, SM
    Detsky, AS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21): : 2801 - 2809
  • [4] Breiman RF, 2003, EMERG INFECT DIS, V9, P1037
  • [5] CAVANAGH D, 2000, PRINCIPLES PRACTICE
  • [6] *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P241
  • [7] Outbreak of severe acute respiratory syndrome in Hong kong special administrative region: case report
    Chan-Yeung, M
    Yu, WC
    [J]. BRITISH MEDICAL JOURNAL, 2003, 326 (7394): : 850 - +
  • [8] Severe acute respiratory syndrome - Patients were epidemiologically linked
    Chan-Yeung, M
    Seto, WH
    Sung, JJY
    [J]. BRITISH MEDICAL JOURNAL, 2003, 326 (7403): : 1393 - 1393
  • [9] Treatment of SARS with human interferons
    Cinatl, J
    Morgenstern, B
    Bauer, G
    Chandra, P
    Rabenau, H
    Doerr, HW
    [J]. LANCET, 2003, 362 (9380) : 293 - 294
  • [10] Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
    Cinatl, J
    Morgenstern, B
    Bauer, G
    Chandra, P
    Rabenau, H
    Doerr, HW
    [J]. LANCET, 2003, 361 (9374) : 2045 - 2046